7-methyl-4-nitro-1H-indole | 10553-07-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 7-methyl-4-nitro-1H-indole
• CAS: 10553-07-8
• 化学式: C₉H₈N₂O₂
• 分子量: 176.175
• InChiKey: PGDQJLNWTYACPC-UHFFFAOYSA-N

物化性质

• 熔点：
  182 °C(Solv: ethanol (64-17-5))
• 沸点：
  378.0±22.0 °C(Predicted)
• 密度：
  1.355±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  7-methyl-4-nitro-1H-indole 在 platinum(IV) oxide 、 palladium 10% on activated carbon 、 氢气 、 sodium ethanolate 、 2-氯-1,3-二甲基氯化咪唑啉 、 sodium hydride 、 potassium carbonate 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 乙腈 、 mineral oil 为溶剂， 反应 16.0h， 生成 N-(4,5-dihydro-1H-imidazol-2-yl)-7-methyl-1H-indol-4-amine
  参考文献：
  名称：

  Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases

  摘要：

  The alternative pathway (AP) of the complement system is a key contributor to the pathogenesis of several human diseases including age-related macular degeneration, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and various glomerular diseases. The serine protease factor B (FB) is a key node in the AP and is integral to the formation of C3 and C5 convertase. Despite the prominent role of FB in the AP, selective orally bioavailable inhibitors, beyond our own efforts, have not been reported previously. Herein we describe in more detail our efforts to identify FB inhibitors by high-throughput screening (HTS) and leveraging insights from several X-ray cocrystal structures during optimization efforts. This work culminated in the discovery of LNP023 (41), which is currently being evaluated clinically in several diverse AP mediated indications.

  DOI：

  10.1021/acs.jmedchem.9b01870
• 作为产物：
  描述：

  2,6-二甲基-3-硝基苯胺 在 potassium ethoxide 、 对甲苯磺酸 、 草酸二乙酯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.5h， 生成 7-methyl-4-nitro-1H-indole
  参考文献：
  名称：

  通过2-烷基硝基苯胺衍生物的闭环合成吲哚

  摘要：

  由草酸二烷基酯促进的碱诱导的环化反应，由2-烷基-3-或5-硝基苯胺的亚氨酸酯，am和仲-苯胺衍生物制备了多种硝基吲哚。结果表明，在一个简单的操作中，基本上相同的方法也可用于合成相应的硝基吲哚-3-乙醛酸酯。讨论了合成潜力，并提出了一种机理。

  DOI：

  10.1016/s0040-4020(01)87932-1

文献信息

• NOVEL 6-5 BICYCIC HETEROCYCLIC DERIVATIVE AND MEDICAL USE THEREOF
  申请人：Sanwa Kagaku Kenkyusho Co., Ltd

  公开号：EP2036887A1

  公开（公告）日：2009-03-18

  An object of the present invention is to provide a medicament as a thyroid hormone receptor ligand which is sufficient in drug efficacy and safety, and has the excellent action as a drug. The present invention provides a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof: [wherein [Chemical Formula 2] is a single bond or a double bond; A is -CH2- or -CO-; X, Y, and Z are each independently a nitrogen atom or a carbon atom; R1 is a hydrogen atom or an aralkyl group; R2 is an alkyl group or an aralkyl group, etc.; R3 is a hydrogen atom or an alkyl group, etc.; R4 is a hydrogen atom or an alkyl group; R5 is a hydrogen atom, an alkyl group or a halo lower alkyl group, etc.; R6 is a hydrogen atom or an alkyl group; R7 is a hydrogen atom, etc.; R8 is a hydrogen atom, or an alkyl group, etc.; and E is -NHCO-G-COR12, etc. (wherein G is a single bond or an alkylene group, and R12 is a hydroxy group or an alkoxy group)].

  本发明的目的是提供一种药物，作为甲状腺激素受体配体，其在药物疗效和安全性上足够，并且具有作为药物的优秀作用。本发明提供了一种由以下通式（I）表示的化合物或其药用可接受的盐：[其中[化学公式2]是单键或双键；A是-CH2-或-CO-；X、Y和Z各自独立为氮原子或碳原子；R1是氢原子或芳烷基团；R2是烷基团或芳烷基团等；R3是氢原子或烷基团等；R4是氢原子或烷基团；R5是氢原子、烷基团或卤素低烷基团等；R6是氢原子或烷基团；R7是氢原子等；R8是氢原子或烷基团等；E是-NHCO-G-COR12等（其中G是单键或亚烷基团，R12是羟基或烷氧基）]。
• Novel N-acylated heterocycles
  申请人：Recordati S.A.

  公开号：US20030162777A1

  公开（公告）日：2003-08-28

  Described are compositions comprising a muscarinic receptor antagonist and an N-acylated heterocycle derivative having affinity for serotonergic receptors, and enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts thereof. The combination of a muscarinic receptor antagonist and an N-acylated heterocycle, or an enantiomer, diastereoisomer, N-oxide, polymorph, solvate or pharmaceutically acceptable salt thereof, is useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT 1A receptors.

  描述了包含一种肌氨酸受体拮抗剂和一种对5-HT 1A 受体具有亲和力的N-酰化杂环衍生物的组合物，以及它们的对映体、二对映体、N-氧化物、多型体、溶剂合物和药用可接受盐。肌氨酸受体拮抗剂和N-酰化杂环，或其对映体、二对映体、N-氧化物、多型体、溶剂合物或药用可接受盐的组合，在治疗患有下尿路神经肌肉功能障碍和与5-HT 1A 受体相关疾病的患者中是有用的。
• Method for dyeing keratinous fibres using an aminoindole in combination
  申请人：L'Oreal

  公开号：US05180400A1

  公开（公告）日：1993-01-19

  Method for dyeing keratinous fibres, characterized in that at least one composition (A) containing at least one aminoindole in a medium appropriate for dyeing is applied to these fibres, the application of the composition (A) being preceded or followed by the application of a composition (B) containing, in a medium appropriate for dyeing, at least one quinone derivative chosen from ortho- or para-benzoquinones, ortho- or para-benzoquinone monoimines or diimines, 1,2- or 1,4-naphthoquinones, ortho- or para-benzoquinone sulphonimides, .alpha.,.omega.-alkylene-bis-1,4-benzoquinones, or 1,2- or 1,4-naphthoquinone monoimines or diimines, the aminoindoles and the quinone derivatives being chosen such that the difference in redox potential .DELTA.E between the redox potential E.sub.i of the aminoindoles, determined at pH 7 in a phosphate medium on a vitreous carbon electrode by voltametry, and the redox potential E.sub.q of the quinone derivative, determined at pH 7 in a phosphate medium by polarography on a mercury electrode relative to the saturated calomel electrode, in such that .DELTA.E=E.sub.i -E.sub.q .ltoreq.470 mV.

  将角蛋白纤维染色的方法，其特征在于至少将至少一种含有至少一种氨基吲哚的组合物（A）应用于适合染色的介质中，然后将该组合物（A）的应用前或后跟随着含有至少一种醌衍生物的组合物（B）的应用，该醌衍生物选择自邻苯醌或对苯醌、邻苯醌或对苯醌单亚胺或二亚胺、1,2-或1,4-萘醌、邻苯醌磺酰亚胺、α，ω-烷基-双1,4-苯醌，或1,2-或1,4-萘醌单亚胺或二亚胺，所选择的氨基吲哚和醌衍生物使得在磷酸盐介质中以伏安法在玻碳电极上测定的pH 7下的氨基吲哚的氧化还原电位E.sub.i和在磷酸盐介质中通过极谱法在pH 7下相对于饱和氯化汞电极测定的醌衍生物的氧化还原电位E.sub.q之间的差值ΔE，即ΔE=E.sub.i -E.sub.q ≤ 470毫伏。
• [EN] HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT<br/>[FR] COMPOSES HETEROCYCLIQUES UTILISES POUR TRAITER DES TROUBLES DE LA VOIE URINAIRE
  申请人：RECORDATI CHEM PHARM

  公开号：WO2003031436A1

  公开（公告）日：2003-04-17

  Compounds of formula (I) are thus useful for treating disorders of the urinary tract. In the compounds I, R1 = one or more substituents selected from H, halogen, OH, alkyl, haloalkyl, alkoxy, haloalkoxy, NO2, nitro, phenyl, substituted phenyl, heterocycle, substituted heterocycle, NR3R4(R3 and R4 being H, alkyl, acyl or alkoxycarbonyl); R2 = one or two substituents selected from H, alkyl; Y = CH2 or a bond; Q = CO, CS or SO2; A = alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heterocyclic, alkylamino, dialkylamino, arylamino or arylalkylamino, each of which is optionally substituted; n is 1 or 2; X = an amino moiety selected from formula (a), (b) and -N(R5)-CH2-(R5 = H, methyl, benzyl group; W = bond, N, CH, CH2, C(CN) C(OH) or C(COCH3) (when W represents a nitrogen atom or a CH, C(CN) C(OH) or C(COCH3) group, the group Z-B attaches to the W ring atom); when X is (a) or (b), Z = bond, O, S, CH2, CH2CH2, CO, CHOH, OCH2, NH, NHCO or NHCONHCH2, but when X is -N(R5)-CH2-group, Z represents a CH2CH2 or CH2O group or Z and B together represent a 2,3-dihydro-benzo[1,4]dioxin-2-yl group; and B is a monocyclic or bicyclic aryl group or a monocyclic or bicyclic heterocycle, each of which is optionally substituted.

  公式（I）的化合物因此对治疗泌尿道疾病有用。在化合物I中，R1 = H，卤素，OH，烷基，卤代烷基，烷氧基，卤代烷氧基，NO2，硝基，苯基，取代苯基，杂环，取代杂环，NR3R4（其中R3和R4为H，烷基，酰基或烷氧羰基）中的一个或多个取代基; R2 = H，烷基中的一个或两个取代基; Y = CH2或键; Q = CO，CS或SO2; A = 烷基，烯基，环烷基，环烯基，芳基，杂环，烷基氨基，二烷基氨基，芳基氨基或芳基烷基氨基，每个取代基都是可选的; n为1或2; X = 公式（a），（b）和-N（R5）-CH2-（R5 = H，甲基，苯甲基）中选择的氨基基团; W = 键，N，CH，CH2，C（CN）C（OH）或C（COCH3）（当W表示氮原子或CH，C（CN）C（OH）或C（COCH3）基团时，基团Z-B附着在W环原子上）; 当X为（a）或（b）时，Z = 键，O，S，CH2，CH2CH2，CO，CHOH，OCH2，NH，NHCO或NHCONHCH2，但当X为-N（R5）-CH2-基团时，Z表示CH2CH2或CH2O基团，或Z和B一起表示2,3-二氢苯并[1,4]二氧杂环-2-基团; B是单环或双环芳基或单环或双环杂环，每个取代基都是可选的。
• NOVEL 6-5 SYSTEM BICYCLIC HETEROCYCLIC DERIVATIVE AND ITS PHARMACEUTICAL UTILITY
  申请人：Asano Yukiyasu

  公开号：US20090176841A1

  公开（公告）日：2009-07-09

  An object of the present invention is to provide a medicament as a thyroid hormone receptor ligand which is sufficient in drug efficacy and safety, and has the excellent action as a drug. The present invention provides a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof: [wherein [Chemical Formula 2] is a single bond or a double bond; A is —CH 2 — or —CO—; X, Y, and Z are each independently a nitrogen atom or a carbon atom; R 1 is a hydrogen atom or an aralkyl group; R 2 is an alkyl group or an aralkyl group, etc.; R 3 is a hydrogen atom or an alkyl group, etc.; R 4 is a hydrogen atom or an alkyl group; R 5 is a hydrogen atom, an alkyl group or a halo lower alkyl group, etc.; R 6 is a hydrogen atom or an alkyl group; R 7 is a hydrogen atom, etc.; R 8 is a hydrogen atom, or an alkyl group, etc.; and E is —NHCO-G-COR 12 , etc. (wherein G is a single bond or an alkylene group, and R 12 is a hydroxy group or an alkoxy group)].

  本发明的目的是提供一种作为甲状腺激素受体配体的药物，具有充分的药效和安全性，并具有优秀的药物作用。本发明提供了以下通式（I）所表示的化合物或其药学上可接受的盐：[其中[化学式2]是单键或双键；A是-CH2-或-CO-；X、Y和Z分别是氮原子或碳原子；R1是氢原子或芳基烷基；R2是烷基或芳基烷基等；R3是氢原子或烷基等；R4是氢原子或烷基；R5是氢原子、烷基或卤代低烷基等；R6是氢原子或烷基；R7是氢原子等；R8是氢原子或烷基等；E是-NHCO-G-COR12等（其中G是单键或烷基亚基，R12是羟基或烷氧基）]。